Ledaga
What Ledaga is used for
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ledaga
- Active substance
- chlormethine
- Disease area
- Mycosis Fungoides
- Medicine group
- Antineoplastic agents
- ATC code
- L01AA05
- Marketing authorisation holder
- Helsinn Birex Pharmaceuticals Ltd.
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ledaga used for?
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
What is the active substance in Ledaga?
Ledaga contains chlormethine.
Who makes Ledaga?
The EU marketing authorisation holder is Helsinn Birex Pharmaceuticals Ltd..
Is Ledaga an orphan medicine?
Yes. Ledaga is designated an orphan medicine in the EU, for a rare disease (Mycosis Fungoides).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU